{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,15]],"date-time":"2026-03-15T05:30:05Z","timestamp":1773552605919,"version":"3.50.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2007,9,5]],"date-time":"2007-09-05T00:00:00Z","timestamp":1188950400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2008,4]]},"DOI":"10.1007\/s00262-007-0397-x","type":"journal-article","created":{"date-parts":[[2007,9,4]],"date-time":"2007-09-04T15:10:20Z","timestamp":1188918620000},"page":"573-579","source":"Crossref","is-referenced-by-count":27,"title":["The fibronectin attachment protein of bacillus Calmette-Guerin (BCG) mediates antitumor activity"],"prefix":"10.1007","volume":"57","author":[{"given":"Haley W.","family":"Sinn","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bennett D.","family":"Elzey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert J.","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiuqin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weicheng","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy L.","family":"Ratliff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2007,9,5]]},"reference":[{"key":"397_CR1","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1016\/S0022-5347(17)38622-6","volume":"145","author":"MJ Becich","year":"1991","unstructured":"Becich MJ, Carroll S, Ratliff TL (1991) Internalization of bacille Calmette-Guerin by bladder tumor cells. J Urol 145:1316\u20131324","journal-title":"J Urol"},{"key":"397_CR2","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/S0022-5347(17)43959-0","volume":"137","author":"WJ Catalona","year":"1987","unstructured":"Catalona WJ, Hudson MA, Gillen DP, Andriole GL, Ratliff TL (1987) Risks and benefits of repeated courses of intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer. J Urol 137:220\u2013224","journal-title":"J Urol"},{"key":"397_CR3","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/S0022-5347(01)65748-3","volume":"156","author":"JL Chin","year":"1996","unstructured":"Chin JL, Kadhim SA, Batislam E, Karlik SJ, Garcia BM, Nickel JC, Morales A (1996) Mycobacterium cell wall: an alternative to intravesical bacillus Calmette Guerin (BCG) therapy in orthotopic murine bladder cancer. J Urol 156:1189\u20131193","journal-title":"J Urol"},{"key":"397_CR4","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1097\/01.ju.0000103100.22951.5e","volume":"171","author":"SM Donat","year":"2004","unstructured":"Donat SM, North A, Dalbagni G, Herr HW (2004) Efficacy of office fulguration for recurrent low grade papillary bladder tumors less than 0.5\u00a0cm. J Urol 171:636\u2013639","journal-title":"J Urol"},{"key":"397_CR5","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/sj.bjc.6690038","volume":"79","author":"MC Filion","year":"1999","unstructured":"Filion MC, Lepicier P, Morales A, Phillips NC (1999) Mycobacterium phlei cell wall complex directly induces apoptosis in human bladder cancer cells. Br J Cancer 79:229\u2013235","journal-title":"Br J Cancer"},{"key":"397_CR6","first-page":"138","volume":"33","author":"J Flamm","year":"1994","unstructured":"Flamm J, Donner G, Bucher A, Holtl W, Albrecht W, Havelec L (1994) Topical immunotherapy (KLH) vs. chemotherapy (Ethoglucid) in prevention of recurrence of superficial bladder cancer. A prospective randomized study. Urologe A 33:138\u2013143","journal-title":"Urologe A"},{"key":"397_CR7","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/S0022-5347(17)37452-9","volume":"147","author":"HW Herr","year":"1992","unstructured":"Herr HW, Wartinger DD, Fair WR, Oettgen HF (1992) Bacillus Calmette-Guerin therapy for superficial bladder cancer: a 10-year followup. J Urol 147:1020\u20131023","journal-title":"J Urol"},{"key":"397_CR8","doi-asserted-by":"crossref","first-page":"32023","DOI":"10.1074\/jbc.274.45.32023","volume":"274","author":"C Horn","year":"1999","unstructured":"Horn C, Namane A, Pescher P, Riviere M, Romain F, Puzo G, Barzu O, Marchal G (1999) Decreased capacity of recombinant 45\/47-kDa molecules (Apa) of Mycobacterium tuberculosis to stimulate T lymphocyte responses related to changes in their mannosylation pattern. J Biol Chem 274:32023\u201332030","journal-title":"J Biol Chem"},{"key":"397_CR9","first-page":"3726","volume":"51","author":"MA Hudson","year":"1991","unstructured":"Hudson MA, Brown EJ, Ritchey JK, Ratliff TL (1991) Modulation of fibronectin-mediated bacillus Calmette-Guerin attachment to murine bladder mucosa by drugs influencing the coagulation pathways. Cancer Res 51:3726\u20133732","journal-title":"Cancer Res"},{"key":"397_CR10","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/j.1365-2249.1995.tb05560.x","volume":"99","author":"AM Jackson","year":"1995","unstructured":"Jackson AM, Alexandroff AB, Kelly RW, Skibinska A, Esuvaranathan K, Prescott S, Chisholm GD, James K (1995) Changes in urinary cytokines and soluble intercellular adhesion molecule-1 (ICAM-1) in bladder cancer patients after bacillus Calmette-Guerin (BCG) immunotherapy. Clin Exp Immunol 99:369\u2013375","journal-title":"Clin Exp Immunol"},{"key":"397_CR11","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/S0934-8840(11)80712-7","volume":"282","author":"C Jurincic-Winkler","year":"1995","unstructured":"Jurincic-Winkler C, Engelmann U, Beuth J, Klippel KF (1995) Efficacy of local Bacillus Calmette-Guerin treatment in superficial bladder cancer relapsing under Keyhole-Limpet Hemocyanin immunotherapy. Zentralbl Bakteriol 282:409\u2013415","journal-title":"Zentralbl Bakteriol"},{"issue":"Suppl 3","key":"397_CR12","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1159\/000052392","volume":"37","author":"CD Jurincic-Winkler","year":"2000","unstructured":"Jurincic-Winkler CD, Metz KA, Beuth J, Klippel KF (2000) Keyhole limpet hemocyanin for carcinoma in situ of the bladder: a long-term follow-up study. Eur Urol 37(Suppl 3):45\u201349","journal-title":"Eur Urol"},{"key":"397_CR13","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1172\/JCI114434","volume":"85","author":"LR Kavoussi","year":"1990","unstructured":"Kavoussi LR, Brown EJ, Ritchey JK, Ratliff TL (1990) Fibronectin-mediated Calmette-Guerin bacillus attachment to murine bladder mucosa. Requirement for the expression of an antitumor response. J Clin Invest 85:62\u201367","journal-title":"J Clin Invest"},{"key":"397_CR14","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1172\/JCI116202","volume":"91","author":"K Kuroda","year":"1993","unstructured":"Kuroda K, Brown EJ, Telle WB, Russell DG, Ratliff TL (1993) Characterization of the internalization of bacillus Calmette-Guerin by human bladder tumor cells. J Clin Invest 91:69\u201376","journal-title":"J Clin Invest"},{"key":"397_CR15","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/S0022-5347(17)53354-6","volume":"128","author":"DL Lamm","year":"1982","unstructured":"Lamm DL, Reichert DF, Harris SC, Lucio RM (1982) Immunotherapy of murine transitional cell carcinoma. J Urol 128:1104\u20131108","journal-title":"J Urol"},{"key":"397_CR16","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0094-0143(21)00423-7","volume":"19","author":"DL Lamm","year":"1992","unstructured":"Lamm DL (1992) Complications of bacillus Calmette-Guerin immunotherapy. Urol Clin North Am 19:565\u2013572","journal-title":"Urol Clin North Am"},{"key":"397_CR17","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/S0022-5347(17)37316-0","volume":"147","author":"DL Lamm","year":"1992","unstructured":"Lamm DL, van der Meijden PM, Morales A, Brosman SA, Catalona WJ, Herr HW, Soloway MS, Steg A, Debruyne FM (1992) Incidence and treatment of complications of bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer. J Urol 147:596\u2013600","journal-title":"J Urol"},{"key":"397_CR18","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/S0022-5347(17)36172-4","volume":"149","author":"DL Lamm","year":"1993","unstructured":"Lamm DL, DeHaven JI, Riggs DR, Ebert RF (1993) Immunotherapy of murine bladder cancer with keyhole limpet hemocyanin (KLH). J Urol 149:648\u2013652","journal-title":"J Urol"},{"key":"397_CR19","first-page":"947","volume":"9","author":"DL Lamm","year":"1995","unstructured":"Lamm DL (1995) BCG immunotherapy for transitional-cell carcinoma in situ of the bladder. Oncology (Williston Park) 9:947\u2013952, discussion 955\u2013965","journal-title":"Oncology (Williston Park)"},{"key":"397_CR20","doi-asserted-by":"crossref","first-page":"4003","DOI":"10.1128\/IAI.63.10.4003-4010.1995","volume":"63","author":"A Laqueyrerie","year":"1995","unstructured":"Laqueyrerie A, Militzer P, Romain F, Eiglmeier K, Cole S, Marchal G (1995) Cloning, sequencing, and expression of the apa gene coding for the Mycobacterium tuberculosis 45\/47-kilodalton secreted antigen complex. Infect Immun 63:4003\u20134010","journal-title":"Infect Immun"},{"key":"397_CR21","doi-asserted-by":"crossref","first-page":"3386","DOI":"10.1158\/0008-5472.CAN-04-0374","volume":"64","author":"AT Ludwig","year":"2004","unstructured":"Ludwig AT, Moore JM, Luo Y, Chen X, Saltsgaver NA, O\u2019Donnell MA, Griffith TS (2004) Tumor necrosis factor-related apoptosis-inducing ligand: a novel mechanism for Bacillus Calmette-Guerin-induced antitumor activity. Cancer Res 64:3386\u20133390","journal-title":"Cancer Res"},{"key":"397_CR22","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/S0022-5347(17)59210-1","volume":"115","author":"A Morales","year":"1976","unstructured":"Morales A, Eidinger D (1976) Bacillus Calmette-Guerin in the treatment of adenocarcinoma of the kidney. J Urol 115:377\u2013380","journal-title":"J Urol"},{"key":"397_CR23","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1016\/S0022-5347(05)65642-X","volume":"166","author":"A Morales","year":"2001","unstructured":"Morales A, Chin JL, Ramsey EW (2001) Mycobacterial cell wall extract for treatment of carcinoma in situ of the bladder. J Urol 166:1633\u20131637; discussion 1637\u20131638","journal-title":"J Urol"},{"key":"397_CR24","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1046\/j.1365-2249.2003.02071.x","volume":"131","author":"R Nadler","year":"2003","unstructured":"Nadler R, Luo Y, Zhao W, Ritchey JK, Austin JC, Cohen MB, O\u2019Donnell MA, Ratliff TL (2003) Interleukin 10 induced augmentation of delayed-type hypersensitivity (DTH) enhances Mycobacterium bovis bacillus Calmette-Guerin (BCG) mediated antitumour activity. Clin Exp Immunol 131:206\u2013216","journal-title":"Clin Exp Immunol"},{"issue":"5","key":"397_CR25","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/s00345-006-0112-0","volume":"24","author":"MA O\u2019Donnell","year":"2006","unstructured":"O\u2019Donnell MA, Boehle A (2006) Treatment options for BCG failures. World J Urol 24(5):481\u2013487","journal-title":"World J Urol"},{"key":"397_CR26","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S0022-5347(17)59919-X","volume":"111","author":"CA Olsson","year":"1974","unstructured":"Olsson CA, Chute R, Rao CN (1974) Immunologic reduction of bladder cancer recurrence rate. J Urol 111:173\u2013176","journal-title":"J Urol"},{"key":"397_CR27","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1016\/S0022-5347(17)54303-7","volume":"127","author":"AS Pang","year":"1982","unstructured":"Pang AS, Morales A (1982) BCG induced murine peritoneal exudate cells: cytotoxic activity against a syngeneic bladder tumor cell line. J Urol 127:1225\u20131229","journal-title":"J Urol"},{"key":"397_CR28","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/S0022-5347(17)39713-6","volume":"144","author":"S Prescott","year":"1990","unstructured":"Prescott S, James K, Hargreave TB, Chisholm GD, Smyth JF (1990) Radio-immunoassay detection of interferon-gamma in urine after intravesical Evans BCG therapy. J Urol 144:1248\u20131251","journal-title":"J Urol"},{"key":"397_CR29","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0022-5347(17)43909-7","volume":"137","author":"TL Ratliff","year":"1987","unstructured":"Ratliff TL, Gillen D, Catalona WJ (1987) Requirement of a thymus dependent immune response for BCG-mediated antitumor activity. J Urol 137:155\u2013158","journal-title":"J Urol"},{"key":"397_CR30","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/S0022-5347(17)35678-1","volume":"150","author":"TL Ratliff","year":"1993","unstructured":"Ratliff TL, Ritchey JK, Yuan JJ, Andriole GL, Catalona WJ (1993) T-cell subsets required for intravesical BCG immunotherapy for bladder cancer. J Urol 150:1018\u20131023","journal-title":"J Urol"},{"key":"397_CR31","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1002\/pros.1130","volume":"49","author":"S Reader","year":"2001","unstructured":"Reader S, Menard S, Filion B, Filion MC, Phillips NC (2001) Pro-apoptotic and immunomodulatory activity of a mycobacterial cell wall-DNA complex towards LNCaP prostate cancer cells. Prostate 49:155\u2013165","journal-title":"Prostate"},{"key":"397_CR32","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1159\/000281474","volume":"44","author":"F Recker","year":"1989","unstructured":"Recker F, Rubben H (1989) Variation of the immunosystem by ciclosporin and keyhole-limpet hemocyanin\u2014are there effects on chemically induced bladder carcinoma? Urol Int 44:77\u201380","journal-title":"Urol Int"},{"key":"397_CR33","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/1471-2407-4-86","volume":"4","author":"C Sanger","year":"2004","unstructured":"Sanger C, Busche A, Bentien G, Spallek R, Jonas F, Bohle A, Singh M, Brandau S (2004) Immunodominant PstS1 antigen of mycobacterium tuberculosis is a potent biological response modifier for the treatment of bladder cancer. BMC Cancer 4:86","journal-title":"BMC Cancer"},{"key":"397_CR34","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1046\/j.1365-2958.1996.6381353.x","volume":"21","author":"JS Schorey","year":"1996","unstructured":"Schorey JS, Holsti MA, Ratliff TL, Allen PM, Brown EJ (1996) Characterization of the fibronectin-attachment protein of Mycobacterium avium reveals a fibronectin-binding motif conserved among mycobacteria. Mol Microbiol 21:321\u2013329","journal-title":"Mol Microbiol"},{"key":"397_CR35","first-page":"1611","volume":"43","author":"A Shapiro","year":"1983","unstructured":"Shapiro A, Ratliff TL, Oakley DM, Catalona WJ (1983) Reduction of bladder tumor growth in mice treated with intravesical Bacillus Calmette-Guerin and its correlation with Bacillus Calmette-Guerin viability and natural killer cell activity. Cancer Res 43:1611\u20131615","journal-title":"Cancer Res"},{"key":"397_CR36","doi-asserted-by":"crossref","first-page":"8250","DOI":"10.1158\/0008-5472.CAN-06-1416","volume":"66","author":"H Suttmann","year":"2006","unstructured":"Suttmann H, Riemensberger J, Bentien G, Schmaltz D, Stockle M, Jocham D, Bohle A, Brandau S (2006) Neutrophil granulocytes are required for effective bacillus calmette-guerin immunotherapy of bladder cancer and orchestrate local immune responses. Cancer Res 66:8250\u20138257","journal-title":"Cancer Res"},{"key":"397_CR37","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1016\/S0022-5347(17)35352-1","volume":"151","author":"RD Swerdlow","year":"1994","unstructured":"Swerdlow RD, Ratliff TL, La Regina M, Ritchey JK, Ebert RF (1994) Immunotherapy with keyhole limpet hemocyanin: efficacy and safety in the MB-49 intravesical murine bladder tumor model. J Urol 151:1718\u20131722","journal-title":"J Urol"},{"key":"397_CR38","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/0305-0491(95)02091-8","volume":"113","author":"RD Swerdlow","year":"1996","unstructured":"Swerdlow RD, Ebert RF, Lee P, Bonaventura C, Miller KI (1996) Keyhole limpet hemocyanin: structural and functional characterization of two different subunits and multimers. Comp Biochem Physiol B Biochem Mol Biol 113:537\u2013548","journal-title":"Comp Biochem Physiol B Biochem Mol Biol"},{"key":"397_CR39","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1016\/0264-410X(95)00084-E","volume":"13","author":"HM Vordermeier","year":"1995","unstructured":"Vordermeier HM, Coombes AG, Jenkins P, McGee JP, O\u2019Hagan DT, Davis SS, Singh M (1995) Synthetic delivery system for tuberculosis vaccines: immunological evaluation of the M. tuberculosis 38\u00a0kDa protein entrapped in biodegradable PLG microparticles. Vaccine 13:1576\u20131582","journal-title":"Vaccine"},{"key":"397_CR40","doi-asserted-by":"crossref","first-page":"4521","DOI":"10.1074\/jbc.274.8.4521","volume":"274","author":"W Zhao","year":"1999","unstructured":"Zhao W, Schorey JS, Groger R, Allen PM, Brown EJ, Ratliff TL (1999) Characterization of the fibronectin binding motif for a unique mycobacterial fibronectin attachment protein, FAP. J Biol Chem 274:4521\u20134526","journal-title":"J Biol Chem"},{"key":"397_CR41","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1002\/(SICI)1097-0215(20000401)86:1<83::AID-IJC13>3.0.CO;2-R","volume":"86","author":"W Zhao","year":"2000","unstructured":"Zhao W, Schorey JS, Bong-Mastek M, Ritchey J, Brown EJ, Ratliff TL (2000) Role of a bacillus Calmette-Guerin fibronectin attachment protein in BCG-induced antitumor activity. Int J Cancer 86:83\u201388","journal-title":"Int J Cancer"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-007-0397-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00262-007-0397-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-007-0397-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,22]],"date-time":"2021-08-22T19:28:37Z","timestamp":1629660517000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00262-007-0397-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,9,5]]},"references-count":41,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2008,4]]}},"alternative-id":["397"],"URL":"https:\/\/doi.org\/10.1007\/s00262-007-0397-x","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,9,5]]}}}